Helix BioPharma (TSE:HBP) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Helix BioPharma Corp. (TSE:HBP – Get Free Report)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$2.07 and traded as low as C$1.60. Helix BioPharma shares last traded at C$1.64, with a volume of 21,111 shares changing hands.

Helix BioPharma Stock Performance

The company has a quick ratio of 1.04, a current ratio of 0.04 and a debt-to-equity ratio of 2.34. The company has a 50 day moving average of C$1.89 and a 200 day moving average of C$2.07. The firm has a market cap of C$125.26 million, a price-to-earnings ratio of -27.33 and a beta of 0.40.

About Helix BioPharma

(Get Free Report)

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.

Read More

• Five stocks we like better than Helix BioPharma
• Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
• Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
• Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
• Water Infrastructure: Why This Boring Sector Could Get Exciting